Paliperidone extended-release for the treatment of schizophrenia.

Paliperidone extended-release for the treatment of schizophrenia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Paliperidone extended-release for the treatment of schizophrenia. Abstract Text:

Abstract Paliperidone, the major active metabolite of risperidone (9-hydroxyrisperidone), is a second-generation antipsychotic that was recently approved by the United States Food and Drug Administration for treatment of acute schizophrenia and for maintenance treatment of schizophrenia. We performed a literature search of PreMEDLINE, MEDLINE, and International Pharmaceutical Abstracts from 1966-October 2007 to review the available data on the pharmacology, pharmacokinetics, clinical evidence, and safety and tolerability profile of paliperidone extended-release (ER). Articles from randomized controlled trials, abstracts, and posters presented at national scientific meetings were included in this review. Paliperidone ER has been shown to be significantly more effective in improving schizophrenic symptoms according to the Positive and Negative Symptom Scale (PANSS), Clinical Global Impressions-Severity Scale, and Personal and Social Performance Scale compared with placebo (p<0.05). In addition, limited evidence suggests similar efficacy between paliperidone ER 6-12 mg/day and risperidone 4-6 mg/day. A 2-week, double-blind comparison with quetiapine demonstrated that paliperidone ER was significantly better than quetiapine in improving PANSS scores (p<0.001). Paliperidone ER appears to be well tolerated at the recommended starting dosage of 6 mg/day. The most commonly reported adverse effect was dose-related extrapyramidal symptoms. Weight gain and metabolic disturbances were minimal. The cost of paliperidone ER appears to be slightly higher than that of other second-generation antipsychotics. Paliperidone ER tablets may be a safe and effective treatment option for acute schizophrenia and maintenance treatment of schizophrenia compared with placebo. Because well-designed comparative data are lacking, an additional benefit over other antipsychotics is yet to be determined.

Paliperidone extended-release for the treatment of schizophrenia. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Paliperidone extended-release for the treatment of schizophrenia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pharmacotherapy

VOLUME: 28

Page Numbers: 1283-98

Journal Abbreviation: Pharmacotherapy

ISSN: 0277-0008

DAY: 30

MONTH: Oct

YEAR: 2008

Paliperidone extended-release for the treatment of schizophrenia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8111305

Paliperidone extended-release for the treatment of schizophrenia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Paliperidone extended-release for the treatment of schizophrenia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Paliperidone extended-release for the treatment of schizophrenia.

AFFILIATION: 1 College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida; Jackson Health Systems, Mental Health Pharmacy, Miami, Florida.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharmacotherapy

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Paliperidone extended-release for the treatment of schizophrenia Related Publications

• An isotopic method for quantifying sweeteners derived from corn and sugar cane.
• Calcified pulmonary metastases from a cardiac angiosarcoma.
• Chemical composition of the spanish spike oil.
• Cloning and expression of Ani s 9, a new Anisakis simplex allergen.
• Cultural Approaches to Diabetes Self-management Programs for the Latino Community.
• Epidemic of childhood obesity: implications for kidney disease.
• Estimating sexual selection and sexual isolation effects from mating frequencies.
• Fat embolism secondary to yellow fat disease in an Appaloosa horse.
• Functional outcome after facial allograft transplantation in rats.
• Genetic impact of the Prestige oil spill in wild populations of a poor dispersal marine snail from intertidal rocky shores.
• Improving diabetes care and education of latinos: a challenging but important mission.
• Insecticidal properties and microbial contaminants in a Spodoptera exigua multiple nucleopolyhedrovirus (Baculoviridae) formulation stored at different temperatures.
• Isotropic compensation of diffraction-driven angular dispersion.
• Lack of nonadditive genetic effects on early fecundity in Drosophila melanogaster.
• Left atrial sarcoma presenting as cerebral infarction.
• Management of subdivided populations in conservation programs: development of a novel dynamic system.
• Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas.
• Molecular weight distributions of industrially-produced poly-(epsilon-caprolactams) by gel permeation chromatography.
• Multiple nodules on the leg. Primary neuroendocrine carcinoma of the skin (PNCS).
• Nonlinear optical waveguides generated in lithium niobate by swift-ion irradiation at ultralow fluences.
• PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses.
• Paliperidone extended-release for the treatment of schizophrenia.
• Patagonian wines: the selection of an indigenous yeast starter.
• Prevalence of overweight among Baltimore City schoolchildren and its associations with nutrition and physical activity.
• Type 2 diabetes in the Hispanic or Latino population: challenges and opportunities.
• [Clinical images in gastroenterology. Pedunculated hepatocarcinoma]
• [Hospital organizational configuration is the key to success in attracting and retaining nurses]
• [Not Available.]
• [Photography as analysis document, body and medicine: theory, method and criticism--the experience of Museo Nacional de Medicina Enrique Laval]
• [Rapid identification and susceptibility to killer toxins of yeasts isolated from non-systemic mycoses]